Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target Cut to $20.00 by Analysts at Piper Sandler

Amphastar Pharmaceuticals (NASDAQ:AMPH) had its price target decreased by Piper Sandler from $21.00 to $20.00 in a research note published on Friday,Benzinga reports. Piper Sandler currently has a neutral rating on the stock.

AMPH has been the subject of a number of other research reports. Jefferies Financial Group reiterated a “hold” rating and issued a $22.00 price objective (down from $30.00) on shares of Amphastar Pharmaceuticals in a report on Tuesday, April 21st. Zacks Research upgraded Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 21st. Bank of America reaffirmed an “underperform” rating and issued a $20.00 price target (down from $25.00) on shares of Amphastar Pharmaceuticals in a report on Monday, June 29th. Barclays reduced their price objective on Amphastar Pharmaceuticals from $23.00 to $20.00 and set an “equal weight” rating on the stock in a research report on Wednesday, June 3rd. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, July 8th. Six equities research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Amphastar Pharmaceuticals has an average rating of “Reduce” and an average target price of $22.00.

Amphastar Pharmaceuticals Price Performance

Amphastar Pharmaceuticals stock opened at $20.78 on Friday. Amphastar Pharmaceuticals has a 52-week low of $16.65 and a 52-week high of $31.26. The firm has a market capitalization of $916.19 million, a price-to-earnings ratio of 12.30, a PEG ratio of 4.18 and a beta of 0.89. The company has a fifty day simple moving average of $19.66 and a 200-day simple moving average of $21.39. The company has a quick ratio of 2.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.79.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.29. The firm had revenue of $183.90 million for the quarter, compared to the consensus estimate of $179.92 million. Amphastar Pharmaceuticals had a net margin of 10.76% and a return on equity of 14.92%. On average, equities analysts anticipate that Amphastar Pharmaceuticals will post 2.25 EPS for the current fiscal year.

Institutional Trading of Amphastar Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Quarry LP acquired a new stake in shares of Amphastar Pharmaceuticals during the 3rd quarter worth approximately $32,000. Farther Finance Advisors LLC lifted its holdings in Amphastar Pharmaceuticals by 46.3% in the fourth quarter. Farther Finance Advisors LLC now owns 1,381 shares of the company’s stock valued at $37,000 after acquiring an additional 437 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Amphastar Pharmaceuticals by 24.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,233 shares of the company’s stock valued at $60,000 after acquiring an additional 435 shares during the last quarter. TD Private Client Wealth LLC grew its position in Amphastar Pharmaceuticals by 410.1% in the fourth quarter. TD Private Client Wealth LLC now owns 2,418 shares of the company’s stock worth $65,000 after acquiring an additional 1,944 shares during the period. Finally, Quadrant Capital Group LLC purchased a new position in Amphastar Pharmaceuticals in the third quarter worth approximately $82,000. Hedge funds and other institutional investors own 65.09% of the company’s stock.

More Amphastar Pharmaceuticals News

Here are the key news stories impacting Amphastar Pharmaceuticals this week:

• Positive Sentiment: Amphastar reported second-quarter revenue of $183.9 million, exceeding analysts’ approximately $179.9 million estimate. Adjusted earnings were $0.91 per share, well above consensus estimates ranging from $0.62 to $0.66 and up from $0.85 a year earlier. GAAP net income totaled $30.3 million, or $0.67 per share, while adjusted net income was $40.8 million. Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026
• Positive Sentiment: The earnings beat was broad enough to attract attention from analysts, with coverage highlighting stronger-than-expected revenue, EPS and other key quarterly metrics. The results provide a positive near-term catalyst for AMPH and help support its valuation despite the stock remaining below its 200-day moving average. Amphastar Pharmaceuticals Q2 Earnings and Revenues Top Estimates
• Neutral Sentiment: Wells Fargo raised its price target from $19 to $20 but maintained an “equal weight” rating. The revised target remains below the recent trading level, signaling limited perceived upside despite the earnings performance. Wells Fargo price-target update
• Negative Sentiment: Piper Sandler lowered its price target from $21 to $20 and assigned a “neutral” rating. The downgrade in target suggests analysts remain cautious about AMPH’s outlook and could temper the positive reaction to the quarterly beat. Piper Sandler price-target update

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.